Hair-loss research is moving quickly, and VDPHL01 has become a closely watched investigational pill in pattern hair loss. For people in Fort Myers comparing hair-restoration options, the key point is that this product remains in clinical development and cannot be prescribed as VDPHL01 today. The 2026 updates provide useful clinical signals, but important questions remain. The next major female trial readout is expected in the first half of 2027.
VDPHL01 is an extended-release oral formulation of minoxidil being studied in women and men with pattern hair loss, also called androgenetic alopecia. The formulation is designed to release minoxidil over time rather than deliver it all at once. The strongest 2026 female data so far came from a small open-label Phase 2 study, meaning participants and investigators knew treatment was being given and there was no placebo comparison. A much larger randomized, double-blind, placebo-controlled female trial is now fully enrolled according to the company. Its 2027 results should provide a clearer test of efficacy and safety.
How to Read the VDPHL01 Headlines Right Now
- VDPHL01 remains investigational. The extended-release oral minoxidil formulation is still being studied and is not an approved VDPHL01 prescription option today.
- The female evidence is still developing. The encouraging 2026 signal came from a 28-woman open-label study, while a much larger controlled trial is expected to report in 2027.
- Current hair changes still deserve evaluation. A widening part, receding hairline, crown thinning, or changing shedding pattern can be assessed without waiting for the next trial milestone.
Address Thinning Hair With Options Available Today
If you are seeing progressive thinning, an individualized evaluation can help clarify the pattern, possible contributors, and options that can actually be considered now. Explore our hair restoration approach before deciding on your next step.
Physician-reviewed content • Evidence-aware care • Personalized treatment planning
Put New Research in a Broader Care Context
Clinical-trial headlines are only one part of a treatment decision. You can review Fountain of Youth’s broader Rejuvenation & Healing services and learn more about our clinic before deciding whether an evaluation makes sense.
What VDPHL01 Is—and Is Not
VDPHL01 is a proprietary investigational tablet containing extended-release minoxidil. It is being developed specifically for pattern hair loss. Clinical trial records describe it as an investigational oral drug, and the development program includes separate studies in female and male pattern hair loss.
Minoxidil itself is not new, but the route, formulation, dose, and intended use matter. Immediate-release oral minoxidil is an approved prescription drug for severe hypertension, and clinicians also use low-dose oral minoxidil off label for some hair-loss patients. An international expert consensus published in 2025 addressed off-label low-dose oral minoxidil for hair loss, including precautions, baseline evaluation, monitoring, and specialty consultation. VDPHL01 is different because it is a specific extended-release product being tested through a registration-directed program for pattern hair loss.
Safety discussions need that same distinction. The current oral minoxidil label for hypertension carries a boxed warning describing serious cardiovascular risks, including fluid around the heart and worsening angina, and calls for close medical supervision. Those warnings apply to the approved immediate-release hypertension product, not a final safety label for VDPHL01. An investigational extended-release formulation still requires careful cardiovascular safety evaluation. Larger and longer controlled trials are central to that assessment.
What the 2026 Results Actually Showed
The July female Phase 2 signal
In July 2026, Veradermics reported results from Study 207, an open-label Phase 2 trial that included 28 adult women with mild-to-moderate pattern hair loss. Women received VDPHL01 4.5 mg either once daily or twice daily for six months. The company reported mean increases in non-vellus target-area hair count of 22.7 hairs per square centimeter with once-daily dosing and 23.3 hairs per square centimeter with twice-daily dosing. These measurements track hair-count change within a defined scalp area rather than guaranteeing visible improvement for every person.
Patient-reported coverage also improved during the study. At month six, 88.9% of the once-daily group and 90.0% of the twice-daily group rated their hair coverage as improved or much improved on the study scale, according to the female Phase 2 results. The company reported no treatment-related serious adverse events and no adverse events of special interest of cardiac origin during the six-month period. Study 207 was small and open label, so it did not include a blinded placebo group to compare against the observed changes. The larger controlled female trial is designed to address that limitation.
What the male program added in 2026
The male development program provides a separate placebo-controlled result. In April 2026, Veradermics reported six-month topline results from Study 302, a randomized, double-blind, placebo-controlled Phase 2/3 trial in 519 men with mild-to-moderate pattern hair loss. Mean non-vellus target-area hair count increased by 30.3 hairs per square centimeter with once-daily VDPHL01 and 33.0 with twice-daily dosing, compared with 7.3 with placebo.
Patient-reported improvement in the male trial also favored the active groups. The company reported that 48.4% of once-daily participants and 62.9% of twice-daily participants rated their coverage as improved or much improved at six months, compared with 13.4% of placebo participants. The placebo comparison helps separate treatment-associated change from change that also occurs in the control group. Twelve-month Study 302 data and topline results from the separate confirmatory male Phase 3 Study 304 were still expected in the second half of 2026 as of the company’s August 11 update.
Research Progress Does Not Require Putting Care on Hold
VDPHL01 may become relevant to future treatment choices, but the current trials do not replace an evaluation of hair loss happening now. Our hair restoration services focus on the pattern, history, and options available at the time of your visit.
Why the 2027 Female Readout Matters More
The female Study 306 is designed to answer questions that Study 207 could not. Veradermics reported in August 2026 that 556 women had been enrolled in the registration-directed Phase 2/3 study, with participants assigned to VDPHL01 or placebo under randomized, double-blind conditions. The company says the study evaluates 4.5 mg once daily and twice daily over 52 weeks, with co-primary endpoints at 24 weeks focused on non-vellus hair count and patient-reported hair coverage. The registered Study 306 design also describes a randomized, double-blind, placebo-controlled trial in women with androgenetic alopecia. Topline results are expected in the first half of 2027.
Randomization helps balance differences between groups, and blinding reduces the influence of expectations on assessments. A placebo comparison gives researchers a reference point for measured hair counts and patient-reported change. A positive result is not automatic, and one trial cannot answer every question about long-term use. Study 306 is nonetheless a more rigorous test of whether the female Phase 2 signal holds up under controlled conditions.
The readout should include more than a positive-or-negative headline. The size of the treatment effect versus placebo, consistency across dose groups, adverse events, discontinuations, and durability of benefit will all matter. Its 24-week co-primary endpoints are central, while the longer study period adds information relevant to a chronic condition. Regulators consider the total development package rather than one percentage or image. A favorable topline announcement would still be a development milestone, not an approval, and the first-half-of-2027 target is the company’s current expectation and could change. Full results may also add details that are absent from an initial announcement.
What This Means for Hair-Restoration Decisions Now
A person noticing a widening part, receding hairline, or gradually thinner crown does not need to wait for a 2027 readout before seeking an evaluation. Pattern hair loss can resemble other causes of shedding or thinning, so a useful visit starts with the pattern and timing of hair change, medication history, scalp symptoms, and previous treatments. Those details help a clinician decide what deserves closer examination. They also provide a baseline for discussing currently available options.
People already using a hair-loss treatment should not stop, start, or change medication solely because of VDPHL01 news. The investigational product is not a substitute for an individualized discussion about treatments available now. At Fountain of Youth in Fort Myers, Florida, staff stays current on hair-restoration developments such as VDPHL01 while keeping investigational options separate from treatments that can actually be considered today.
Medical history is especially relevant whenever an oral medication may affect blood pressure or fluid balance. Clinicians may need to review cardiovascular history, other medications, symptoms such as dizziness or swelling, and other factors before discussing oral minoxidil use in general. Existing oral minoxidil prescribing for hair loss is off label, which is not the same as access to VDPHL01. A future VDPHL01 approval, if it occurs, would come with official labeling, dosing instructions, contraindications, and safety information. Until then, trial updates are a reason to ask informed questions rather than attempt self-treatment.
What to Bring to a Hair-Loss Evaluation
A few concrete details can make a hair-loss visit more productive and help distinguish a long-term pattern from a sudden change. Bring what you can without delaying care; the goal is to give the clinician a clearer timeline and medication picture.
| Bring or note | Why it helps | Useful detail |
|---|---|---|
| Photos over time | Shows progression more clearly than memory alone | Use similar lighting, angle, part, and hairstyle when possible |
| Medication list | Helps identify possible contributors and interaction concerns | Include prescriptions, over-the-counter products, and recent changes |
| Hair-loss timeline | Helps separate gradual thinning from abrupt shedding | Note when it started and whether the pace changed |
| Scalp symptoms | May point toward a condition needing a different evaluation | Mention itching, burning, flaking, tenderness, or visible inflammation |
| Relevant health history | Provides context for medication and diagnostic decisions | Include blood-pressure issues, heart or kidney history, and recent major illness when applicable |
When a Hair-Loss Evaluation May Be Worth Considering
VDPHL01 news is most useful when it is kept separate from the question of what your own hair changes mean. An evaluation may be particularly useful when the cause, pace, or appropriate treatment path is still unclear.
- Your part is widening, hairline is receding, or crown density is gradually changing. A progressive pattern can provide useful diagnostic context when viewed alongside your history.
- Shedding started suddenly or accelerated recently. A change that does not resemble your previous pattern may warrant a closer look before choosing a treatment.
- You are already using a hair-loss treatment and want your plan reviewed. Medication history, treatment response, blood-pressure considerations, and other health factors can affect the discussion.
The goal is to identify a sensible next step based on your current presentation rather than on an investigational drug’s future timeline.
For history review, medication follow-up, or treatment planning that does not require an in-person scalp examination, ask whether TeleHealth is appropriate for your situation.
Questions Patients Are Asking
Is VDPHL01 available by prescription now?
No. VDPHL01 remains an investigational extended-release oral minoxidil product in clinical development for pattern hair loss. A clinician may discuss other treatments that are currently available, including situations where oral minoxidil is prescribed off label, but that is not the same as prescribing VDPHL01. Availability would require successful development and any necessary regulatory approval.
Do the 2026 female results prove the pill works?
No. The July 2026 female results showed increases in hair counts and patient-reported coverage during treatment, but Study 207 was small and open label. Without a placebo group and blinding, it cannot make the same treatment-versus-control comparison as Study 306, which is designed to provide that comparison.
What should I watch for in the 2027 results?
Compare VDPHL01 with placebo on both co-primary endpoints rather than focusing only on the headline. The size of the difference, adverse-event pattern, discontinuations, dose results, and consistency of benefit will all matter. Longer follow-up can also show whether six-month findings persist and whether new safety information appears. Any regulatory decision would depend on the broader evidence package.
Does extended release automatically mean fewer side effects?
No. Extended release describes how a drug is formulated to deliver its active ingredient over time; it does not by itself prove a safer outcome for a particular use. The VDPHL01 development program is collecting safety data for this formulation and patient population, and controlled longer-duration results are needed to define that profile more fully.
Move From Research Headlines to a Personal Plan
If the VDPHL01 research has prompted questions about your own thinning or shedding, review Fountain of Youth’s hair restoration information and schedule a consultation when you are ready to discuss available options.
Keeping the Timeline in Perspective
VDPHL01 is worth watching because the program now includes encouraging 2026 signals and larger controlled studies. The male Study 302 results provide a six-month placebo comparison, while the female Study 207 results provide an early uncontrolled signal. The fully enrolled female Study 306 is the central 2027 event because it tests efficacy and safety under randomized, double-blind, placebo-controlled conditions. Male Study 304 and the 12-month Study 302 update may add context before then. None of those milestones guarantees approval, and expected readout dates can move. Patients can follow the research without putting current hair-loss decisions on hold.
For someone dealing with thinning hair today, the practical move is to document the pattern, get the cause evaluated, and discuss currently available options in light of personal health history. VDPHL01 may eventually change the conversation around oral treatment for pattern hair loss, but the next steps depend on data still being collected and reviewed. The 2027 female readout should show whether the early signal holds up against placebo. Until then, VDPHL01 remains an investigational treatment rather than a do-it-yourself option.
Questions? We are here to help! Call 239-355-3294.
Medical review: Reviewed by Dr. Keith Lafferty MD, Fort Myers on September 10, 2026. Fact-checked against government and academic sources; see in-text citations. This page follows our Medical Review & Sourcing Policy .
